000			nab a22 7a 4500
999			_c17253 _d17253
003			PC17253
005			20230222134851.0
008			230222b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9206 _aOrigüen Sabater, Julia _eEnfermedades Infecciosas
100			_9263 _aFernández Ruiz, Mario _eMedicina Interna
100			_9873 _aLumbreras Bermejo, Carlos _eMedicina Interna
100			_91619 _aOrellana Miguel, María Ángeles _eMicrobiología y Parasitología
100			_9162 _aLópez Medrano, Francisco _eEnfermedades Infecciosas
100			_93199 _aRuiz Merlo, Tamara _eEnfermedades Infecciosas
100			_9869 _aSan Juan Garrido, Rafael _eMedicina Interna
100			_91210 _aGarcía Reyne, Ana _eMedicina Interna
100			_9876 _aAguado García, José María _eEnfermedades Infecciosas
100			_91487 _aGonzález Monte, Esther _eNefrología
100			_92138 _aPolanco Fernández, Natalia _eNefrología
100			_91321 _aAndrés Belmonte, Amado _eNefrología
100			_91510 _aPaz Artal, Estela _eInmunología
245	0	0	_aPotential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case-control study. _h[artículo]
260			_bInfection, _c2015
300			_a43(4):413-22.
500			_aFormato Vancouver: Origüen J, Fernández Ruiz M, Lumbreras C, Orellana MÁ, López Medrano F, Ruiz Merlo T et al. Potential role of post-transplant hypogammaglobulinemia in the risk of Clostridium difficile infection after kidney transplantation: a case-control study. Infection. 2015 Aug;43(4):413-22.
501			_aPMID: 25676130
504			_aContiene 41 referencias
520			_aPurpose: To identify reversible risk factors for Clostridium difficile infection (CDI) after kidney transplantation (KT) that could lead to a reduction in its incidence and associated complications. Methods: We performed a single-center case-control study in which 41 patients undergoing KT between February 2009 and July 2013 who developed a first episode of post-transplant CDI were included as cases. Patients transplanted at the same calendar day (± 2 weeks) as each case with no evidence of CDI and comparable risk exposure period were chosen as controls (2:1 ratio). Serum immunoglobulin and complement levels were systematically measured at baseline and months 1 and 6 after transplantation. Results: Multivariate regression analysis identified age-adjusted Charlson comorbidity index (odds ratio [OR] per unitary increment 1.31; P value = 0.043), delayed graft function (OR 2.76; P value = 0.039), prior cytomegalovirus (CMV) disease (OR 6.85; P value = 0.011) and prior acute graft rejection (OR 5.92; P value = 0.008) as risk factors for post-transplant CDI. Cases with their first episode of CDI occurring beyond the first month were more likely to have IgG hypogammaglobulinemia (HGG) at month 1 (P value = 0.002), whereas cases with CDI beyond the sixth month were more likely to have HGG of any class at month 6 (P value = 0.003). Poor outcome (graft loss and/or all-cause mortality) was more common among cases (adjusted hazard ratio 5.69; P value = 0.001). Conclusion: The occurrence of CDI exerts a detrimental effect on graft and patient outcome. Post-transplant HGG was a potentially modifiable risk factor for CDI in KT recipients.
710			_96 _aServicio de Medicina Interna
710			_981 _aServicio de Microbiología y Parasitología
710			_986 _aServicio de Nefrología
710			_9395 _aServicio de Inmunología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17253.pdf _ySolicitar documento
942			_2ddc _cART _n0